Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma

Judith Michels; Nathalie Lassau; Marine Gross-Goupil; Christophe Massard; Arnaud Mejean; Bernard Escudier

doi:10.1007/s10637-009-9275-z

Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma

Judith Michels, Nathalie Lassau, Marine Gross-Goupil, Christophe Massard, Arnaud Mejean, Bernard Escudier

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

21 Citations (Scopus)

Résumé

Summary: Sunitinib is an oral antityrosine kinase inhibitor that has antiangiogenic and antitumor activities. It has been approved for the treatment of advanced RCC and for imatinib-refractory gastrointestinal stromal tumors (GIST). Tumor lysis syndrom can occur in solid tumors. We report a case of patient with metastatic RCC treated with sunitinib with a diagnosis of tumor lysis syndrome.

langue originale	Anglais
Pages (de - à)	690-693
Nombre de pages	4
journal	Investigational New Drugs
Volume	28
Numéro de publication	5
Les DOIs	https://doi.org/10.1007/s10637-009-9275-z
état	Publié - 1 oct. 2010

Accès au document

10.1007/s10637-009-9275-z

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{ab8933992e6444db9692182d5e06b9e3,

title = "Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma",

abstract = "Summary: Sunitinib is an oral antityrosine kinase inhibitor that has antiangiogenic and antitumor activities. It has been approved for the treatment of advanced RCC and for imatinib-refractory gastrointestinal stromal tumors (GIST). Tumor lysis syndrom can occur in solid tumors. We report a case of patient with metastatic RCC treated with sunitinib with a diagnosis of tumor lysis syndrome.",

keywords = "Renal cell carcinoma, Sunitinib, Tumor lysis syndrome",

author = "Judith Michels and Nathalie Lassau and Marine Gross-Goupil and Christophe Massard and Arnaud Mejean and Bernard Escudier",

year = "2010",

month = oct,

day = "1",

doi = "10.1007/s10637-009-9275-z",

language = "English",

volume = "28",

pages = "690--693",

journal = "Investigational New Drugs",

issn = "0167-6997",

number = "5",

}

TY - JOUR

T1 - Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma

AU - Michels, Judith

AU - Lassau, Nathalie

AU - Gross-Goupil, Marine

AU - Massard, Christophe

AU - Mejean, Arnaud

AU - Escudier, Bernard

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Summary: Sunitinib is an oral antityrosine kinase inhibitor that has antiangiogenic and antitumor activities. It has been approved for the treatment of advanced RCC and for imatinib-refractory gastrointestinal stromal tumors (GIST). Tumor lysis syndrom can occur in solid tumors. We report a case of patient with metastatic RCC treated with sunitinib with a diagnosis of tumor lysis syndrome.

AB - Summary: Sunitinib is an oral antityrosine kinase inhibitor that has antiangiogenic and antitumor activities. It has been approved for the treatment of advanced RCC and for imatinib-refractory gastrointestinal stromal tumors (GIST). Tumor lysis syndrom can occur in solid tumors. We report a case of patient with metastatic RCC treated with sunitinib with a diagnosis of tumor lysis syndrome.

KW - Renal cell carcinoma

KW - Sunitinib

KW - Tumor lysis syndrome

UR - http://www.scopus.com/inward/record.url?scp=77956057336&partnerID=8YFLogxK

U2 - 10.1007/s10637-009-9275-z

DO - 10.1007/s10637-009-9275-z

M3 - Article

C2 - 19547920

AN - SCOPUS:77956057336

SN - 0167-6997

VL - 28

SP - 690

EP - 693

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 5

ER -